To date, no studies have evaluated the cost-effectiveness of human papillomavirus (HPV)
vaccination in countries in the Extended Middle East and North Africa (EMENA) region. We …

Using population and epidemiologic data for 48 countries in sub-Saharan Africa, we used a
model-based approach to estimate cervical cancer cases and deaths averted, disability …

Cervical cancer is the leading cause of cancer morbidity and mortality in women in sub-
Saharan Africa (SSA), accounting for about 50,000 deaths annually. Until recently, cytology …

Background While human papillomavirus (HPV) vaccines have been available since 2006,
the coverage has varied among countries. Our aim is to analyse the equity impact of HPV …

Objective To estimate the health impact, financial costs, and cost‐effectiveness of scaling‐up
coverage of human papillomavirus (HPV) vaccination (young girls) and cervical cancer …

Using mathematical models of cervical cancer for the northern and southern regions of
Vietnam, we assessed the cost-effectiveness of cervical cancer prevention strategies and …

Background Human papillomavirus (HPV) vaccines have the potential to reduce cervical
cancer incidence and mortality, particularly in the parts of the developing world that bear the …

Objective: Cervical cancer is a huge public health issue in Morocco which represents the
second most frequent and fatal cancer among women. Countries that have not yet …

Summary Background The WHO Director-General has issued a call for action to eliminate
cervical cancer as a public health problem. To help inform global efforts, we modelled …

Background Estonia has high cervical cancer incidence and low screening coverage. We
modelled the impact of population-based bivalent, quadrivalent or nonavalent HPV …